Using several measures, FAK inhibitor significantly reduced liver fibrosis, including decreased liver collagen production and deposition (Fig. 6A and C), decreased fibrotic lesions (Fig. 6B), and decreased α-SMA expression and collagen expression in liver tissues (Fig. 6D and E). This evidence concerns the gene ACTA1 and Hepatic fibrosis.